NCT06990087View on ClinicalTrials.gov

T-cell Therapy in Patients With PML

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

Progressive Multifocal Leucoencephalopathy (PML)

Interventions

DRUG

Application of T-lymphocytes

Dosage form: Infusion; Route of administration: Intravenous; Cell dose: 1-2 x 10.000 viable CD3+ T-lymphocytes per kg bodyweight; Application at three timepoints: baseline, after two weeks, after 6 weeks

All Listed Sponsors

lead

Hannover Medical School

OTHER

NCT06990087 - T-cell Therapy in Patients With PML | Biotech Hunter | Biotech Hunter